Cure8 research brief
Many people on ustekinumab who lose response wonder whether increasing dosing frequency helps. This prospective study suggests that empiric intensification to every 4 or 6 weeks raised drug levels and was linked with clinical improvement without new safety concerns in a small cohort.
Adults with Crohn’s disease or ulcerative colitis on ustekinumab who have secondary loss of response; gastroenterologists and clinicians managing biologic dosing; researchers studying dose-optimization for biologics.
This was a prospective, non-randomized cohort of 19 adults (12 CD, 7 UC) who underwent empiric ustekinumab dose intensification to q4w or q6w for secondary loss of response. Clinical activity scores were used (HBI for CD, SCCAI for UC).
The primary endpoint was steroid-free clinical remission after the third intensified dose; secondary outcomes included clinical response, fecal calprotectin changes, serum ustekinumab concentrations, and adverse events.
The study reports increased serum ustekinumab levels and high clinical remission/response rates, while biochemical (fecal calprotectin) improvements were modest. No new safety signals or discontinuations for adverse events were observed.
If you’re considering dose intensification: this study provides prospective, but small-scale, evidence that intensifying ustekinumab to every 4 or 6 weeks can raise drug levels and is associated with clinical improvement for some patients.
Talk with your gastroenterologist about whether intensified dosing is appropriate, and whether monitoring (symptoms, fecal calprotectin, and drug levels) is useful for your situation.
This is a small (n=19) prospective cohort from a journal abstract-level report. Results are encouraging but limited by sample size, non-randomized design, and modest biochemical responses. Larger randomized trials would better define effectiveness, optimal intensified interval (q4w vs q6w), and long-term safety.
Review the original publication for the complete reporting, methods, and context.
This Cure8 brief is based on source text from the linked article. Cure8 is informational only and is not a substitute for professional medical advice, diagnosis, or treatment.
People with IBD and their clinicians want ways to predict which advanced therapy will work best. This review summarizes current evidence and shows that, despite many studies, no biomarker is reliably ready for routine...
This trial directly tests common clinical strategies for managing loss of response to ustekinumab in Crohn’s disease. The findings may change whether doctors routinely escalate to 4-weekly dosing after an IV reinduction,...
Patients considering switching biologics or clinicians choosing a second‑line therapy may care because the study suggests ustekinumab had better long‑term persistence and improving remission rates compared with anti‑TNF...
